CollPlant Biotechnologies to Participate in September Investor Conferences

Rhea-AI Summary

CollPlant Biotechnologies (Nasdaq: CLGN) announced participation in upcoming investor conferences. Deputy CEO and CFO Eran Rotem will engage with investors at the HC Wainwright 24th Annual Global Investment Conference on September 12-13 and the Alliance Global Partners MedTech Conference on September 21. CollPlant focuses on innovative collagen-based technologies for tissue regeneration and organ manufacturing. The company has also partnered with Allergan and 3D Systems to advance its product offerings in aesthetic and regenerative medicine.

REHOVOT, Israel, Sept. 6, 2022 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing innovative human collagen-based technologies and products for tissue regeneration and organ manufacturing, today announced that Deputy CEO and CFO Eran Rotem will participate in investor conferences later this month.

• HC Wainwright 24^th Annual Global Investment Conference: Participate in investor meetings on Monday and Tuesday, September 12-13.
  
  
• Alliance Global Partners MedTech Conference: Virtual investor meetings on Wednesday, September 21.

About CollPlant

CollPlant is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs, and medical aesthetics. The Company's products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing, and are ushering in a new era in regenerative and aesthetic medicine.

At the beginning of 2021, CollPlant entered into a development and global commercialization agreement for dermal and soft tissue fillers with Allergan, an AbbVie company, the global leader in the dermal filler market. Later in 2021, CollPlant entered a strategic co-development agreement with 3D Systems for a 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures in combination with an implant.

For more information about CollPlant, visit http://www.collplant.com/

Photo - https://mma.prnewswire.com/media/1772558/CollPlant.jpg

Contact at CollPlant:

Eran Rotem
Deputy CEO & CFO
Tel: + 972-73-2325600
Email: Eran@collplant.com  

View original content:https://www.prnewswire.com/news-releases/collplant-biotechnologies-to-participate-in-september-investor-conferences-301618106.html

SOURCE CollPlant

FAQ

What investor conferences will CollPlant Biotechnologies attend in September 2022?

CollPlant will attend the HC Wainwright 24th Annual Global Investment Conference on September 12-13 and the Alliance Global Partners MedTech Conference on September 21.

Who is representing CollPlant Biotechnologies at the investor conferences?

Deputy CEO and CFO Eran Rotem will represent CollPlant at the investor conferences.

What is the focus of CollPlant Biotechnologies?

CollPlant focuses on developing human collagen-based technologies for tissue regeneration and organ manufacturing.

What recent partnerships has CollPlant established?

CollPlant has formed partnerships with Allergan for dermal fillers and 3D Systems for 3D bioprinted regenerative soft tissue matrices.

What is the stock symbol for CollPlant Biotechnologies?

The stock symbol for CollPlant Biotechnologies is CLGN.